Drug intelligence / Profile preview

Product-118

Development stage: Unknown
Lead developer: PREXA SANTÉ
Administration: Oral

Overview

**Product-118** is an investigational therapeutic agent developed by PREXA SANTÉ for the treatment of COVID-19. Preliminary top-line results from a human clinical trial demonstrated high efficacy after just a few days of once-daily oral dosing, with positive FDA guidance received through a pre-IND response. No specific mechanism of action, chemical structure, or detailed preclinical data are publicly available; further development details remain limited.[1][3]

Beyond the preview

Go deeper on Product-118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Product-118.

Explore the full profile